FOR IMMEDIATE RELEASE
April 3, 2025 — The Age Management Medicine Group (AMMG) has long championed the forefront of regenerative therapies, bringing breakthrough research and clinical applications to physicians worldwide. Now, with U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. publicly endorsing the potential of exosomes, peptides, and stem cells, these once-niche therapies are entering the national healthcare conversation.
Kennedy has voiced strong criticism of regulatory barriers that limit patient access to regenerative treatments and recently led a national roundtable on expanding clinical use. “We need to remove the barriers that prevent patients from accessing promising, science-based therapies like stem cells and peptides,” he said in a recent interview.
Adding to the momentum, the upcoming resignation of Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (CBER), effective April 5, has sparked widespread speculation about regulatory shifts ahead. AMMG is closely monitoring these developments and remains committed to equipping physicians to stay ahead of change.
Attendees at the AMMG April 2025 Conference in Miami will gain exclusive access to the latest clinical advances in regenerative medicine, with sessions and hands-on workshops led by pioneers in the field.
Clinical Highlights:
- Stem Cell Therapy: A 2022 meta-analysis in Stem Cells Translational Medicine showed mesenchymal stem cell (MSC) therapy significantly improved mobility and reduced pain in over 80% of osteoarthritis patients.
- Peptides: Compounds such as BPC-157 and Thymosin Beta-4 are showing promise in musculoskeletal healing, immune modulation, and neuroregeneration.
- Exosomes: A 2023 study in The American Journal of Sports Medicine found exosome injections delivered lasting improvements in joint function for knee osteoarthritis. A 2022 pilot trial in Frontiers in Neuroscience showed early cognitive gains in Alzheimer’s patients receiving exosome-based interventions.
“As the medical community and public leaders recognize the potential of these therapies, AMMG remains the go-to resource for cutting-edge, clinically relevant education,” said Dr. George Shapiro, AMMG faculty member. “Our upcoming conference offers an unparalleled opportunity to learn from experts leading this new medical frontier.”
Looking Ahead:
As policy reform gains traction and clinical evidence builds, AMMG anticipates expanded access to exosomes, peptides, and stem cell therapies in the next 12–24 months. The organization’s mission remains clear: to ensure physicians are prepared to lead the next wave of personalized, regenerative care.
The AMMG April Conference is just weeks away and offers a comprehensive program tailored to practitioners ready to integrate these therapies into their practice.
Learn more and register at www.agemed.org